Saturday, July 11, 2026

pharma · Polycythemia Vera (PV) · Primary Myelofibrosis

PharmaEssentia

PharmaEssentia clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Burlington, USA HQ
2003 Founded
356 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Burlington, USA
Founded
2003
Employees
356
Programs
2
Drugs
3
Patents
0
Intelligence · Clinical Programs

PharmaEssentia projects

2 ClinicalTrials.gov programs sponsored by PharmaEssentia.

PharmaEssentia has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. P1101

    PharmaEssentia

    Polycythemia Vera (PV)

    phase 3 small molecule completed

    1 trial
  2. Ropeginterferon alfa-2b

    PharmaEssentia

    Primary Myelofibrosis

    phase 3 mab active

    1 trial

Frequently asked questions

How many clinical projects does PharmaEssentia have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.